Richmond L, et al. - Researchers attempted to scrutinize the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. The results divulged that biosimilar infliximab was as effective as originator infliximab. Its use appeared to be linked to significant cost savings.